Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

171.00 +10.34 (+6.43%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Belite Bio to Participate in Four Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Virtual Commercial Day on September 2, 2026
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Participate in Four Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Leerink Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
From Belite Bio, Inc
Via GlobeNewswire
InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs
Via Investor Brand Network
News headline image
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
From Belite Bio, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.